These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 24838681)

  • 1. Hypofibrinolysis in type 2 diabetes: the role of the inflammatory pathway and complement C3.
    Hess K; Alzahrani SH; Price JF; Strachan MW; Oxley N; King R; Gamlen T; Schroeder V; Baxter PD; Ajjan RA
    Diabetologia; 2014 Aug; 57(8):1737-41. PubMed ID: 24838681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel mechanism for hypofibrinolysis in diabetes: the role of complement C3.
    Hess K; Alzahrani SH; Mathai M; Schroeder V; Carter AM; Howell G; Koko T; Strachan MW; Price JF; Smith KA; Grant PJ; Ajjan RA
    Diabetologia; 2012 Apr; 55(4):1103-13. PubMed ID: 21918806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of type 2 diabetes on fibrin clot properties in patients with coronary artery disease.
    Neergaard-Petersen S; Hvas AM; Kristensen SD; Grove EL; Larsen SB; Phoenix F; Kurdee Z; Grant PJ; Ajjan RA
    Thromb Haemost; 2014 Dec; 112(6):1142-50. PubMed ID: 25187394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maturity onset diabetes of the young and fibrin-related thrombosis risk.
    Sagar RC; Phoenix F; Thanabalasingham G; Naseem K; Ajjan RA; Owen KR
    Diab Vasc Dis Res; 2020; 17(6):1479164120963048. PubMed ID: 33334146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis.
    Konieczynska M; Fil K; Bazanek M; Undas A
    Thromb Haemost; 2014 Apr; 111(4):685-93. PubMed ID: 24306139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type 2 Diabetes and Cardiovascular Factors Contrasted with Fibrinolysis Disorders in the Blood of Patients with Peripheral Arterial Disease.
    Wieczór R; Wieczór AM; Kulwas A; Rość D
    Medicina (Kaunas); 2019 Jul; 55(7):. PubMed ID: 31336615
    [No Abstract]   [Full Text] [Related]  

  • 7. Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes.
    Kahn SE; Zinman B; Haffner SM; O'Neill MC; Kravitz BG; Yu D; Freed MI; Herman WH; Holman RR; Jones NP; Lachin JM; Viberti GC;
    Diabetes; 2006 Aug; 55(8):2357-64. PubMed ID: 16873701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
    Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
    Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes.
    Festa A; Williams K; Tracy RP; Wagenknecht LE; Haffner SM
    Circulation; 2006 Apr; 113(14):1753-9. PubMed ID: 16585388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced Plasma Magnesium Levels in Type-1 Diabetes Associate with Prothrombotic Changes in Fibrin Clotting and Fibrinolysis.
    Sobczak AIS; Phoenix FA; Pitt SJ; Ajjan RA; Stewart AJ
    Thromb Haemost; 2020 Feb; 120(2):243-252. PubMed ID: 31942750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1.
    Aso Y; Matsumoto S; Fujiwara Y; Tayama K; Inukai T; Takemura Y
    Metabolism; 2002 Apr; 51(4):471-6. PubMed ID: 11912556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered plasma fibrin clot properties in essential thrombocythemia.
    Małecki R; Gacka M; Kuliszkiewicz-Janus M; Jakobsche-Policht U; Kwiatkowski J; Adamiec R; Undas A
    Platelets; 2016; 27(2):110-6. PubMed ID: 25989112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement C3 is a novel plasma clot component with anti-fibrinolytic properties.
    Howes JM; Richardson VR; Smith KA; Schroeder V; Somani R; Shore A; Hess K; Ajjan R; Pease RJ; Keen JN; Standeven KF; Carter AM
    Diab Vasc Dis Res; 2012 Jul; 9(3):216-25. PubMed ID: 22253322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
    Chudý P; Kotuličová D; Staško J; Kubisz P
    Blood Coagul Fibrinolysis; 2011 Sep; 22(6):493-8. PubMed ID: 21519232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrinogen interaction with complement C3: a potential therapeutic target to reduce thrombosis risk.
    King RJ; Schuett K; Tiede C; Jankowski V; John V; Trehan A; Simmons K; Ponnambalam S; Storey RF; Fishwick CWG; McPherson MJ; Tomlinson DC; Ajjan RA
    Haematologica; 2021 Jun; 106(6):1616-1623. PubMed ID: 32354869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unfavorably altered fibrin clot properties in patients with active rheumatoid arthritis.
    Kwasny-Krochin B; Gluszko P; Undas A
    Thromb Res; 2010 Jul; 126(1):e11-6. PubMed ID: 20471669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gender-specific alterations in fibrin structure function in type 2 diabetes: associations with cardiometabolic and vascular markers.
    Alzahrani SH; Hess K; Price JF; Strachan M; Baxter PD; Cubbon R; Phoenix F; Gamlen T; Ariëns RA; Grant PJ; Ajjan RA
    J Clin Endocrinol Metab; 2012 Dec; 97(12):E2282-7. PubMed ID: 22996148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma Protein Oxidation as a Determinant of Impaired Fibrinolysis in Type 2 Diabetes.
    Bryk AH; Konieczynska M; Rostoff P; Broniatowska E; Hohendorff J; Malecki MT; Undas A
    Thromb Haemost; 2019 Feb; 119(2):213-222. PubMed ID: 30605917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased incorporation of antiplasmin into the fibrin network in patients with type 1 diabetes.
    Agren A; Jörneskog G; Elgue G; Henriksson P; Wallen H; Wiman B
    Diabetes Care; 2014 Jul; 37(7):2007-14. PubMed ID: 24760258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of plasminogen activator inhibitor-1, tissue type plasminogen activator antigen, fibrinogen, and D-dimer levels in various age decades in patients with type 2 diabetes mellitus and stable coronary artery disease (from the BARI 2D trial).
    McBane RD; Hardison RM; Sobel BE;
    Am J Cardiol; 2010 Jan; 105(1):17-24. PubMed ID: 20102884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.